Anne Wojcicki, former chief executive of 23andMe, won a bid to acquire the genetic testing company she founded in a second ...

U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data ...

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

This trial evaluated the safety and efficacy of the combination of Regeneron’s Lynozyfic (linvoseltamab), a B-cell maturation ...

TTAM Research Institute, a non-profit public benefit company also founded by Wojcicki, won the auction with a $305 million ...

Former CEO Anne Wojcicki has prevailed in the bankruptcy auction of 23andMe, its consumer and biopharma research businesses, ...

Beleaguered genetic testing company 23andMe announced Friday that it has reached an agreement to sell itself to TTAM Research ...

Kiniksa Pharmaceuticals sees strong growth from Arcalyst, aided by Medicare redesign. Learn about 2025 sales outlook & ...

Data presented at EHA 2025 demonstrated that the Epkinly / R-ICE combination produced an 87% ORR in transplant-eligible r/r ...

If approved by the court, the 23andMe sale would put Anne Wojcicki back at the helm of the company she co-founded and previously attempted to take private.

23andMe struck a deal last month with Regeneron Pharmaceuticals Inc., but Wojcicki complained about the bidding process, ...

The DNA data of more than 15 million customers of DNA testing firm 23andMe is set to be returned to the control of 23andMe co ...